Lipocine Inc. quarterly report, Q2 FY2012

Business context and reporting period

Entity mismatch: The request identifies Lipocine Inc., but the supplied 10-Q is for Marathon Bar Corp., a Delaware development-stage company. This summary reflects the supplied filing, not Lipocine.

The filing covers the quarter and six months ended June 30, 2012. Marathon was formed in October 2011 and planned to import and sell healthy energy snack bars under its own brand, using third-party suppliers. It had not begun operations or generated revenue.

Financial results and liquidity

At June 30, 2012, cash was $3,434, current liabilities were $4,139, and stockholders’ deficit was $705. There was no reported debt apart from $238 due to shareholders, described as unsecured, non-interest-bearing and payable on demand. No meaningful revenue or operating margins were reported.

Six-month financing cash inflow was $40,500, reported as proceeds from common stock; cash declined by $19,509 from year-end 2011. The filing describes a $50,000 share subscription and $9,500 of offering costs, which is consistent with the net financing amount but should be checked against the underlying records.

Changes versus the prior comparable period

For the three and six months ended June 30, 2011, the filing reports no revenue, expenses, or net loss. The company had no operating cash flow in those comparison periods. The 2012 losses principally reflect filing, professional, consulting, and other administrative costs.

Cash fell from $22,943 at December 31, 2011 to $3,434 at June 30, 2012. During the first half of 2012, the company issued 500,000 shares for stated gross proceeds of $50,000; shares outstanding increased from 3,000,000 to 3,500,000.

Outlook, risks and other items

• Management said the company still needed to complete its capital raise and implement its business plan. Its plans included further market, legal and regulatory research, supplier selection, partnership arrangements, and website development. It expected to become fully functional within 12 months following the capital raise; this was a plan, not a guarantee.
• The filing states that the auditor issued a going-concern opinion and that cash resources were insufficient for the current business plan. Management said additional capital was necessary and that financing might not be available on acceptable terms or at all.
• The officer and director indicated he might provide unsecured loans to support reporting expenses for 12 months if other proceeds were unavailable, but there was no contract or written commitment.
• The company had filed an offering registration statement to sell up to 1,500,000 shares at $0.10 per share for up to $150,000. The filing reports 500,000 shares accepted for subscription in April 2012; completion of the remaining offering was uncertain.
• The filing reports no material legal proceedings, off-balance-sheet arrangements, or material uncertain tax positions. Deferred tax assets were fully offset by a valuation allowance.
• Management concluded disclosure controls and procedures were effective at June 30, 2012. The cover page marks “No” for having filed all required Exchange Act reports during the preceding 12 months; investors should verify the filing history and reporting status.

Important facts for investors to verify

1. Confirm the issuer identity: the provided filing is Marathon Bar Corp., not Lipocine Inc.
2. Verify the status and proceeds of the registered share offering, including the treatment of the $9,500 offering costs and the reported $40,500 net stock proceeds.
3. Assess near-term funding needs and whether any additional financing or director support was secured after the filing date.
4. Check whether the company implemented its supplier, product, and marketing plans or generated revenue after June 30, 2012.
5. Confirm the going-concern disclosure and the company’s compliance with periodic reporting requirements.